Join the community - networking, discussion and more. Open to all.
More informationCould you write an interesting article for the RQA community?
More informationMeeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 7-10 March 2022
Delivering High Standards in Medicines Advertising Regulation, 2021 Annual Report
MHRA Webinar: Medicines Supply to Northern Ireland
MRC announces plans to halve carbon footprint by 2030, 14th March 2022
Safety Observer Article - RSI in Clinical Trials: MHRA Findings and Tips
UK Research and Innovation (UKRI) has signed a shared commitment to improve public involvement in health and social care research.
Compliance Monitor process (Part 1) – An introduction
Presentations and recording - HPP webinar: “Political and legal issues linked to financing the development of pharmaceuticals all along their life-cycle” (03 March 2021)
The regulation reinforcing EMA’s role in crisis preparedness and management of medicinal products and medical devices becomes applicable as of 1st March 2022. It puts some of the structures and processes established by EMA during the COVID-19 pandemic on a more permanent footing, while entrusting several new tasks to the Agency.
Human and Veterinary Highlights from 2021